Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15807MR)

This product GTTS-WQ15807MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15807MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1520MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-011
GTTS-WQ15468MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ9211MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ14769MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ14775MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ1320MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ7471MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ5013MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c4G7-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW